Bad Times For Breakthrough Drugs Targeting Chemo Complications; Submissions From BMS, Merck
The latest news about applications under FDA review, from the Pink Sheet’s US FDA Performance Tracker
You may also be interested in...
Having looked at four prominent drug candidates which are expecting important top-line data this quarter, with the help of Biomedtracker's Q2 Outlook Report, we take a look at four other assets that could soon break into the US market, from infectious diseases to diabetes.
Advisory committee review of combo with ublituximab may provide forum to discuss the Phase III data showing increased risk of death that prompted US FDA safety alert.
TG expects overall survival hazard ratios to move closer to those of existing CLL drugs. Some analysts called a drop in the company’s shares overblown.